Identification of ALP+/CD73+ defining markers for enhanced osteogenic potential in human adipose-derived mesenchymal stromal cells by mass cytometry.
Adipose-derived mesenchymal stromal cells
Cell subpopulation
CyTOF
Multidimensional analysis
Osteogenic potential
Stromal vascular fraction
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
06 01 2021
06 01 2021
Historique:
received:
07
09
2020
accepted:
23
11
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
6
7
2021
Statut:
epublish
Résumé
The impressive progress in the field of stem cell research in the past decades has provided the ground for the development of cell-based therapy. Mesenchymal stromal cells obtained from adipose tissue (AD-MSCs) represent a viable source for the development of cell-based therapies. However, the heterogeneity and variable differentiation ability of AD-MSCs depend on the cellular composition and represent a strong limitation for their use in therapeutic applications. In order to fully understand the cellular composition of MSC preparations, it would be essential to analyze AD-MSCs at single-cell level. Recent advances in single-cell technologies have opened the way for high-dimensional, high-throughput, and high-resolution measurements of biological systems. We made use of the cytometry by time-of-flight (CyTOF) technology to explore the cellular composition of 17 human AD-MSCs, interrogating 31 markers at single-cell level. Subcellular composition of the AD-MSCs was investigated in their naïve state as well as during osteogenic commitment, via unsupervised dimensionality reduction as well as supervised representation learning approaches. This study showed a high heterogeneity and variability in the subcellular composition of AD-MSCs upon isolation and prolonged culture. Algorithm-guided identification of emerging subpopulations during osteogenic differentiation of AD-MSCs allowed the identification of an ALP+/CD73+ subpopulation of cells with enhanced osteogenic differentiation potential. We could demonstrate in vitro that the sorted ALP+/CD73+ subpopulation exhibited enhanced osteogenic potential and is moreover fundamental for osteogenic lineage commitment. We finally showed that this subpopulation was present in freshly isolated human adipose-derived stromal vascular fractions (SVFs) and that could ultimately be used for cell therapies. The data obtained reveal, at single-cell level, the heterogeneity of AD-MSCs from several donors and highlight how cellular composition impacts the osteogenic differentiation capacity. The marker combination (ALP/CD73) can not only be used to assess the differentiation potential of undifferentiated AD-MSC preparations, but also could be employed to prospectively enrich AD-MSCs from the stromal vascular fraction of human adipose tissue for therapeutic applications.
Sections du résumé
BACKGROUND
The impressive progress in the field of stem cell research in the past decades has provided the ground for the development of cell-based therapy. Mesenchymal stromal cells obtained from adipose tissue (AD-MSCs) represent a viable source for the development of cell-based therapies. However, the heterogeneity and variable differentiation ability of AD-MSCs depend on the cellular composition and represent a strong limitation for their use in therapeutic applications. In order to fully understand the cellular composition of MSC preparations, it would be essential to analyze AD-MSCs at single-cell level.
METHOD
Recent advances in single-cell technologies have opened the way for high-dimensional, high-throughput, and high-resolution measurements of biological systems. We made use of the cytometry by time-of-flight (CyTOF) technology to explore the cellular composition of 17 human AD-MSCs, interrogating 31 markers at single-cell level. Subcellular composition of the AD-MSCs was investigated in their naïve state as well as during osteogenic commitment, via unsupervised dimensionality reduction as well as supervised representation learning approaches.
RESULT
This study showed a high heterogeneity and variability in the subcellular composition of AD-MSCs upon isolation and prolonged culture. Algorithm-guided identification of emerging subpopulations during osteogenic differentiation of AD-MSCs allowed the identification of an ALP+/CD73+ subpopulation of cells with enhanced osteogenic differentiation potential. We could demonstrate in vitro that the sorted ALP+/CD73+ subpopulation exhibited enhanced osteogenic potential and is moreover fundamental for osteogenic lineage commitment. We finally showed that this subpopulation was present in freshly isolated human adipose-derived stromal vascular fractions (SVFs) and that could ultimately be used for cell therapies.
CONCLUSION
The data obtained reveal, at single-cell level, the heterogeneity of AD-MSCs from several donors and highlight how cellular composition impacts the osteogenic differentiation capacity. The marker combination (ALP/CD73) can not only be used to assess the differentiation potential of undifferentiated AD-MSC preparations, but also could be employed to prospectively enrich AD-MSCs from the stromal vascular fraction of human adipose tissue for therapeutic applications.
Identifiants
pubmed: 33407847
doi: 10.1186/s13287-020-02044-4
pii: 10.1186/s13287-020-02044-4
pmc: PMC7789251
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Références
Regen Ther. 2020 Feb 20;14:136-153
pubmed: 32110683
J Cell Biochem. 1999 Dec 1;75(3):424-36
pubmed: 10536366
Cytotherapy. 2013 Aug;15(8):893-904
pubmed: 23751203
J Bone Miner Res. 1997 Sep;12(9):1335-47
pubmed: 9286749
Stem Cells. 2006 Feb;24(2):376-85
pubmed: 16322640
Nat Protoc. 2015 Feb;10(2):316-33
pubmed: 25612231
Exp Cell Res. 2005 Aug 15;308(2):283-90
pubmed: 15925364
Stem Cells. 2006 Nov;24(11):2582-91
pubmed: 16873762
FASEB J. 2003 Aug;17(11):1401-10
pubmed: 12890693
Nat Mater. 2017 Mar;16(3):379-389
pubmed: 27798620
J R Soc Interface. 2006 Oct 22;3(10):589-601
pubmed: 16971328
J Cell Sci. 2006 Jun 1;119(Pt 11):2204-13
pubmed: 16684817
Stem Cells Int. 2016;2016:6737345
pubmed: 27057174
Drug Discov Today. 2015 Oct;20(10):1169-75
pubmed: 26092491
Cell Biol Int. 1996 Aug;20(8):579-87
pubmed: 8938992
Methods. 2016 Apr 15;99:62-8
pubmed: 26384580
Nat Commun. 2017 Apr 06;8:14825
pubmed: 28382969
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
Histochem Cell Biol. 2005 Aug;124(2):113-21
pubmed: 16032396
Curr Opin Pharmacol. 2010 Jun;10(3):322-30
pubmed: 20189453
Dev Biol. 1987 May;121(1):1-9
pubmed: 3569655
Bone. 2003 Dec;33(6):919-26
pubmed: 14678851
Tissue Eng. 2001 Apr;7(2):211-28
pubmed: 11304456
J Cell Biochem. 2012 Sep;113(9):2806-12
pubmed: 22511358
J Biosci Bioeng. 2020 Feb;129(2):250-257
pubmed: 31506241
J Cell Physiol. 2006 Jul;208(1):64-76
pubmed: 16557516
J Oral Implantol. 2020 Jul 22;:
pubmed: 32699891
Stem Cells Dev. 2012 Dec 10;21(18):3258-69
pubmed: 22931482
J Orthop Traumatol. 2008 Jun;9(2):73-80
pubmed: 19384620
J Biomech. 2010 Jan 5;43(1):128-36
pubmed: 19828149
Purinergic Signal. 2009 Jun;5(2):205-21
pubmed: 19224395
Stem Cells Dev. 2011 Sep;20(9):1549-61
pubmed: 21204633
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):25-36
pubmed: 30580568
Nature. 2008 May 22;453(7194):519-23
pubmed: 18497825
Nat Mater. 2014 Jun;13(6):645-52
pubmed: 24633344
Stem Cells Transl Med. 2016 May;5(5):591-601
pubmed: 27034413
Int J Mol Sci. 2020 Apr 09;21(7):
pubmed: 32283864
PLoS One. 2016 Apr 13;11(4):e0153207
pubmed: 27074138
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Exp Biol Med (Maywood). 2009 Jan;234(1):1-9
pubmed: 19109553
Tissue Cell. 2017 Oct;49(5):545-551
pubmed: 28720305
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Cytotherapy. 2016 Jan;18(1):41-52
pubmed: 26563474
Bone. 2008 Jul;43(1):32-39
pubmed: 18456590
J Immunol. 2007 Aug 1;179(3):1595-604
pubmed: 17641026
Science. 1999 Apr 2;284(5411):143-7
pubmed: 10102814
Nature. 1988 Dec 15;336(6200):684-7
pubmed: 3143916
Cytometry A. 2013 May;83(5):483-94
pubmed: 23512433
Science. 2011 May 6;332(6030):687-96
pubmed: 21551058
Stem Cell Reports. 2017 Apr 11;8(4):947-960
pubmed: 28344004
Exp Hematol. 2005 Nov;33(11):1402-16
pubmed: 16263424
Cell Tissue Kinet. 1970 Oct;3(4):393-403
pubmed: 5523063
Eur Cell Mater. 2017 Oct 27;34:217-231
pubmed: 29076514
Biochim Biophys Acta. 2008 May;1783(5):673-94
pubmed: 18302942
Injury. 2014 Jun;45(6):974-80
pubmed: 24650943
Stem Cells Dev. 2007 Feb;16(1):91-104
pubmed: 17348807
J Immunol. 1991 Dec 1;147(11):3690-5
pubmed: 1658149
J Bone Miner Res. 1999 Jul;14(7):1115-22
pubmed: 10404011
Stem Cell Res Ther. 2019 Feb 26;10(1):69
pubmed: 30808403
J Cell Physiol. 2001 Oct;189(1):54-63
pubmed: 11573204
Nat Med. 2019 Aug;25(8):1290-1300
pubmed: 31332391
Cell Biochem Funct. 2008 Aug;26(6):664-75
pubmed: 18636461
Cytotherapy. 2013 Sep;15(9):1098-105
pubmed: 23800730
Nat Cell Biol. 2007 Mar;9(3):255-67
pubmed: 17293855